Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 6:10:872.
doi: 10.3389/fphar.2019.00872. eCollection 2019.

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis

Lazaros I Sakkas  1 , Efterpi Zafiriou  2 , Dimitrios P Bogdanos  1
Affiliations
Review

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis

Lazaros I Sakkas et al. Front Pharmacol. .

Abstract

Psoriasis, an inflammatory skin disease, and psoriatic arthritis (PsA), an inflammatory arthritis, share clinical, genetic, and pathogenic factors and may be summed as one disease, the psoriatic disease. Interleukin (IL)-17 plays a major role in the development of both psoriasis and PsA. IL-23 is important in the proliferation and maintenance of IL-17, and therefore, cytokines of the IL-23/IL-17 axis attracted much interest as therapeutic targets in psoriasis and PsA. Therapeutic agents targeting the IL-23/IL-17 axis have been proven to be very effective in psoriasis and PsA, some are already in the therapeutic armamentarium and others are in the development. Some agents, target IL-23 and others IL-17 and include anti-IL-12/IL-23 p40 (ustekinumab, briankizumab), anti-IL-23p19 (guselkumab, tildrakizumab, risankizumab, brazikumab, mirikizumab), anti-IL-17A (secukinumab, ixekizumab), dual anti-IL-17A and anti-IL-17F (bimekizumab), or anti-IL-17 receptor (brodalumab) monoclonal antibodies. Janus tyrosine kinase(JAK) inhibitors also directly affect IL-23 and, thus, IL-17. After the first-generation pan-JAK inhibitors have been shown efficacy (tofacitinib, baricitinib), new-generation selective JAK inhibitors (filgotinib, upadacitinib) are under investigation in psoriasis and PsA.

Keywords: IL-17; anti-IL-17; cytokine; monoclonal antibodies; psoriatic disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
IL-23/IL-17 axis is the focus of novel treatments targeting either cytokine or cytokine receptors.
See this image and copyright information in PMC

References

    1. Benham H., Norris P., Goodall J., Wechalekar M. D., FitzGerald O., Szentpetery A., et al. (2013). Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res. Ther. 15 (5), R136. 10.1186/ar4317 - DOI - PMC - PubMed
    1. Blauvelt A., Gooderham M., Iversen L., Ball S., Zhang L., Agada N. O., et al. (2017. a). Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J. Am. Acad. Dermatol. 77 (5), 855–862. 10.1016/j.jaad.2017.06.153 - DOI - PubMed
    1. Blauvelt A., Papp K. A., Griffiths C. E., Randazzo B., Wasfi Y., Shen Y. K., et al. (2017. b). Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J. Am. Acad. Dermatol. 76 (3), 405–417. 10.1016/j.jaad.2016.11.041 - DOI - PubMed
    1. Boutet M. A., Nerviani A., Gallo Afflitto G., Pitzalis C. (2018). Role of the IL-23/IL-17 Axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int. J. Mol. Sci. 19 (2). 10.3390/ijms19020530 - DOI - PMC - PubMed
    1. Chang S. H., Dong C. (2011). Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell. Signal 23 (7), 1069–1075. 10.1016/j.cellsig.2010.11.022 - DOI - PMC - PubMed